| Expression pattern: |
UP |
| Associated gene: |
hnRNP L, hnRNP A1, pre-EPHB2, RRBP1, GRP78 mRNA, ATF6p50, ATF6 |
| Associated microRNA: |
- |
| Biological function: |
promotes oxaliplatin/5-FU chemoresistance by relieving ER stress and inhibiting apoptosis in recipient CRC cells via exosomal transfer |
| Molecular mechanism: |
Fn infection promotes hsa_circ_0004085 formation via hnRNP L and exosomal packaging via hnRNP A1; exosomal hsa_circ_0004085 binds RRBP1 to enhance GRP78 mRNA stability and promotes ATF6p50 nuclear translocation, activating UPR components to relieve ER stress and confer chemoresistance |
| Biological pathway or process: |
ERK (not specified); apoptosis (inhibits); ER stress (inhibits); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Survival Analysis; Transfection; CCK8; Colony Formation Assay; EdU Staining; Annexin V/PI Flow Cytometry; In Vivo Animal Model; IHC (Immunohistochemistry); IF (Immunofluorescence); H&E Staining; RIP (RNA Immunoprecipitation); RNA Pull-Down; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
High plasma hsa_circ_0004085 before therapy is associated with poor response to oxaliplatin/5-FU and shorter progression-free survival (PFS). |
| Description: |
hsa_circ_0004085 is upregulated in Fn-infected CRC and enriched in tumor-derived exosomes, which transfer it to recipient cells. It binds RRBP1 to stabilize GRP78 mRNA and promotes ATF6p50 nuclear translocation, relieving ER stress, inhibiting apoptosis, and promoting oxaliplatin/5-FU resistance. High plasma levels predict poor chemotherapy response and shorter PFS. |
| Confidence score: |
0.8793 |